Natus Medical Inc. (BABY) to Release Earnings on Wednesday
Natus Medical Inc. (NASDAQ:BABY) is set to announce its Q316 earnings results on Wednesday, October 19th.
Shares of Natus Medical Inc. (NASDAQ:BABY) opened at 40.15 on Tuesday. Natus Medical Inc. has a 12-month low of $29.54 and a 12-month high of $51.05. The firm has a market cap of $1.30 billion, a P/E ratio of 34.61 and a beta of 0.78. The firm has a 50-day moving average price of $41.05 and a 200-day moving average price of $37.00.
BABY has been the subject of a number of research analyst reports. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target for the company in a report on Tuesday, September 13th. Benchmark Co. initiated coverage on Natus Medical in a report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price target for the company. Finally, Zacks Investment Research downgraded Natus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, September 28th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/18/natus-medical-inc-baby-to-release-earnings-on-wednesday.html
In related news, insider James B. Hawkins acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, September 28th. The stock was purchased at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the purchase, the insider now directly owns 459,725 shares in the company, valued at $17,690,218. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.80% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of BABY. BlackRock Inc. increased its position in shares of Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock worth $117,000 after buying an additional 820 shares during the last quarter. Invictus RG increased its position in shares of Natus Medical by 8.7% in the second quarter. Invictus RG now owns 4,200 shares of the company’s stock worth $159,000 after buying an additional 336 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Natus Medical during the second quarter worth approximately $302,000. Clinton Group Inc. increased its position in shares of Natus Medical by 0.7% in the second quarter. Clinton Group Inc. now owns 8,614 shares of the company’s stock worth $326,000 after buying an additional 64 shares during the last quarter. Finally, Raymond James & Associates increased its position in shares of Natus Medical by 2.5% in the second quarter. Raymond James & Associates now owns 14,900 shares of the company’s stock worth $563,000 after buying an additional 367 shares during the last quarter. Hedge funds and other institutional investors own 88.00% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.